FDA Approved Indications for this Orphan Drug:

For chronic replacement therapy of individuals having congenital deficiency of alpha1- proteinase inhibitor with clinically demonstrable panacinar emphysema.

FDA Marketing Approval issued as of:
12/02/1987

Orphan Drug exclusivity ends on:
12/02/1994
Company Making and Marketing this drug:
Bayer Corporation

FDA Designation Date:
12/7/84

FDA Drug Designation:
For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.